drugset / Trial / NCT01346787

Carfilzomib, Cyclophosphamide and Dexamethasone In Newly Diagnosed Multiple Myeloma Patients

NCT01346787

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine whether the association of Carfilzomib, Cyclophosphamide and Dexamethasone (CCd) as induction treatment is safe and provides benefits in patients with newly diagnosed Multiple Myeloma (MM).

Timeline

Start
2011-07
Primary completion
2012-10
Completion
2023-05-31

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Carfilzomib Other / unclassified 36 mg/m2 Intravenous
Subject Cyclophosphamide Other / unclassified 300 mg/m2 Oral
Subject Dexamethasone Small molecule 20 mg Oral
Subject Dexamethasone Small molecule 40 mg Oral

Indications